A standardized staining protocol for L1CAM on formalin-fixed, paraffin-embedded tissues using automated platforms

International Journal of Biological Markers

Volumn 29, Issue 2, 2014, Pages

  Fogel, Mina ^a   Harari, Ayelet ^a   Müller Holzner, Elisabeth ^b   Zeimet, Alain G ^b   Moldenhauer, Gerhard ^c   Altevogt, Peter ^c  

^a KAPLAN MEDICAL CENTER   (Israel)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Antibody; Immunohistochemistry; Ovarian carcinoma

Indexed keywords

ANTIBODY; FORMALDEHYDE; NERVE CELL ADHESION MOLECULE L1; PARAFFIN;

ANTIBODY DILUTION; ANTIGEN RETRIEVAL; ARTICLE; AUTOMATIC SLIDE STAINER; CANCER PROGNOSIS; CONTROLLED STUDY; DILUTION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCUBATION TIME; NEOPLASM; STAINING; STANDARDIZATION; TISSUE FIXATION; TISSUE SECTION; CHEMISTRY; FEMALE; OVARY TUMOR; PATHOLOGY;

FEMALE; FORMALDEHYDE; HUMANS; IMMUNOHISTOCHEMISTRY; NEURAL CELL ADHESION MOLECULE L1; OVARIAN NEOPLASMS; PARAFFIN EMBEDDING; TISSUE FIXATION;

EID: 84903382284     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000055     Document Type: Article

References (17)

1. Fogel M, Gutwein P, Mechtersheimer S, et al. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet. 2003; 362(9387): 869-875.
2. Fogel M, Mechtersheimer S, Huszar M, et al. L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. Cancer Lett. 2003; 189(2): 237-247.
3. Gavert N, Conacci-Sorrell M, Gast D, et al. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol. 2005; 168(4): 633-642.
4. Boo YJ, Park JM, Kim J, et al. L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann Surg Oncol. 2007; 14(5): 1703-1711.
5. Geismann C, Morscheck M, Koch D, et al. Up-regulation of L1CAM in pancreatic duct cells is transforming growth factor beta1-and slug-dependent: role in malignant transformation of pancreatic cancer. Cancer Res. 2009; 69(10): 4517-4526.
6. Doberstein K, Wieland A, Lee SB, et al. L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells. Carcinogenesis. 2011; 32(3): 262-270.
7. Choi SY, Jo YS, Huang SM, et al. L1 cell adhesion molecule as a novel independent poor prognostic factor in gallbladder carcinoma. Hum Pathol. 2011; 42(10): 1476-1483.
8. Li S, Jo YS, Lee JH, et al. L1 cell adhesion molecule is a novel independent poor prognostic factor of extrahepatic cholangiocarcinoma. Clin Cancer Res. 2009; 15(23): 7345-7351.
9. Tischler V, Pfeifer M, Hausladen S, et al. L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. Mol Cancer. 2011; 10(1): 127.
10. Bondong S, Kiefel H, Hielscher T, et al. Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-NB activation. Ann Oncol. 2012; 23(7): 1795-1802.
11. Tsutsumi S, Morohashi S, Kudo Y, et al. L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma. J Surg Oncol. 2011; 103(7): 669-673.
12. Bergmann F, Wandschneider F, Sipos B, et al. Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma. Oncol Rep. 2010; 24(4): 909-915.
13. Kiefel H, Bondong S, Erbe-Hoffmann N, et al. L1CAM-integrin interaction induces constitutive NF-kappaB activation in pancreatic adenocarcinoma cells by enhancing IL-1beta expression. Oncogene. 2010; 29(34): 4766-4778.
14. Kiefel H, Bondong S, Hazin J, et al. L1CAM: a major driver for tumor cell invasion and motility. Cell Adhes Migr. 2012; 6(4): 374-384.
15. Gavert N, Ben-Shmuel A, Lemmon V, Brabletz T, Ben-Ze'ev A. Nuclear factor-kappaB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. J Cell Sci. 2010; 123(Pt 12): 2135-2143.
16. Zeimet AG, Reimer D, Huszar M, et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst. 2013; 105(15): 1142-1150.
17. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M. Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol. 2006; 37(8): 1000-1008.